Program
praliciguat
Also written as “IW-1973”, “Praliciguat (Part A)” and “Praliciguat (Part B)”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Glomerulosclerosis, Focal Segmental · Heart Failure, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ironwood Pharmaceuticals | 50 open or running | phase 2since Sep 15, 2016 | Oct 29, 2015 | none ahead |
| Akebia Therapeutics | 31 open or running | phase 2since Jul 12, 2017 | Jul 12, 2017 | Jun 2027phase 2 · NCT07268638 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2015First study: phase 1 study in HealthyNew to Ironwood PharmaceuticalsIronwood Pharmaceuticals · NCT02616861 · 54 enrolled · United States
- Sep 15, 2016Phase 2 study in Diabetes Mellitus, Type 2Ironwood Pharmaceuticals · NCT02906579 · 11 enrolled · United States
- Mar 8, 2017Phase 2 study in Diabetes Mellitus, Type 2Ironwood Pharmaceuticals · NCT03091920 · 26 enrolled · United States
- Jul 12, 2017Akebia Therapeutics's first study: phase 2 study in Type 2 Diabetes Mellitus With Diabetic NephropathyNew to Akebia TherapeuticsAkebia Therapeutics · NCT03217591 · 156 enrolled · United States
- Aug 16, 2017Phase 2 study in Heart FailureAkebia Therapeutics · NCT03254485 · 196 enrolled · United States, Canada
- Apr 9, 2018Phase 1 study in HealthyIronwood Pharmaceuticals · NCT03499106 · 24 enrolled · United States
- Jan 24, 2019Phase 1 study in Healthy VolunteersIronwood Pharmaceuticals · NCT03818295 · 8 enrolled · United States
- Nov 26, 2025Phase 2 study in Glomerulosclerosis, Focal SegmentalAkebia Therapeutics · NCT07268638 · 60 planned · United States
Ahead
- Jun 2027Primary completion: phase 2 study in Glomerulosclerosis, Focal SegmentalAkebia Therapeutics · NCT07268638
TargetBeta
“Soluble guanylate cyclase activator”ChEMBL 37, by rule
Other programs on the same 4 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Nitroglycerinrule | mediquest-therapeutics | phase 4 | 14 |
| ataciguatrule | Sanofi | phase 3 | 3 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07268638Glomerulosclerosis, Focal Segmental · United States | 2 | Recruiting | Akebia Therapeutics | Jun 2027 | 60 |
| NCT03818295Healthy Volunteers · United States | 1 | Completed | Ironwood Pharmaceuticals | Apr 24, 2019 | 8 |
| NCT03499106Healthy · United States | 1 | Completed | Ironwood Pharmaceuticals | Jul 6, 2018 | 24 |
| NCT03254485Heart Failure · United States, Canada | 2 | Completed | Akebia Therapeutics | Aug 19, 2019 | 196 |
| NCT03217591Type 2 Diabetes Mellitus With Diabetic Nephropathy · United States | 2 | Completed | Akebia Therapeutics | Aug 20, 2019 | 156 |
| NCT03091920Diabetes Mellitus, Type 2 · United States | 2 | Completed | Ironwood Pharmaceuticals | Aug 3, 2017 | 26 |
| NCT02906579Diabetes Mellitus, Type 2 · United States | 2 | Completed | Ironwood Pharmaceuticals | Mar 17, 2017 | 11 |
| NCT02616861Healthy · United States | 1 | Completed | Ironwood Pharmaceuticals | May 2016 | 54 |
How it is read
Names in the registry
- “IW-1973”, 7 entries
- “Praliciguat (Part A)”, 1 entry
- “Praliciguat (Part B)”, 1 entry
- “[14C]-praliciguat”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 3 studies
- Glomerulosclerosis, Focal Segmental, 1 study
- Heart Failure, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.